“…AIRR sequencing (AIRR-seq) provides insights into the immune status of an individual at steady-state or in altered conditions such as malignancy, autoimmune disease, immunodeficiency, infectious disease, or vaccination, and allows comparison of B- and T-cell populations between individuals and time points ( Benichou et al, 2012 ; Kirsch et al, 2015 ; Dziubianau et al, 2013 ; Hou et al, 2016 ; Ghraichy et al, 2018 ). AIRR-seq permits the description and quantification of global diversity and characteristics of AIRR, the identification of clonal expansions, the tracking of particular clonotypes, and the prediction of their specificities ( Miho et al, 2018 ; Zvyagin et al, 2020 ; Sidhom et al, 2018 ; Glanville et al, 2017 ; Huang et al, 2020 ; Jokinen et al, 2021 ; Akbar et al, 2021 ; Hayashi et al, 2021 ) as well as the antibody selection through phage display ( Rouet et al, 2018 ; Ravn et al, 2013 ), thereby providing opportunities for new biomarker identification ( Gittelman, 2021 ; Dines, 2020 ), therapeutic antibody discovery ( Akbar et al, 2021 ; Richardson et al, 2021 ), CAR-T cell bioengineering ( Sheih et al, 2020 ), vaccine development, cancer diagnostics and treatment ( Linette et al, 2019 ; Zhang et al, 2018 ; Lu et al, 2018 ), including neoantigen discovery ( Chiou et al, 2021 ; Richters et al, 2019 ) and immune intervention monitoring in diverse pathologies, such as stem cell transplantation ( Robinson, 2015 ; Fink, 2019 ; Jiang et al, 2019 ; Jacobsen et al, 2017 ; Theil, 2017 ; Link-Rachner et al, 2019 ; Rubelt et al, 2017 ; Parola et al, 2018 ; Georgiou et al, 2014 ; Arnaout et al, 2021 ; Anand et al, 2021 ).…”